Pharmaceutical company Takeda has announced it has entered a global strategic partnership with biotechnology company Innovent Biologics to develop next-generation medicines for cancer tumours.  The agreement will see the development, manufacturing and commercialisation of two late-stage oncology medicines, IBI363 and IBI343, worldwide outside of Greater China. IBI63 is being evaluated in non-small cell lung and […]